The tweet was deleted by the author.
But we saved everything 🙂.
Greenwich LifeSciences, Inc. has announced the pursuit of new patent claims stemming from the statistically significant open label immune response and recurrence rate data generated in its FLAMINGO-01 study.
The company suggests these updated claims could enhance the intellectual property protection associated with its lead immunotherapy candidate as clinical results demonstrate further potential. No additional details on the patent filing timeline or scope were disclosed.
Greenwich LifeSciences previously outlined its upcoming plans for the AACR Meeting, indicating ongoing company developments related to its pipeline projects. Details of the update were disclosed in the company’s announcement regarding its AACR Meeting plans. The company continues to report progress tied to its immunotherapy candidate.